Aubrey de Grey on Progress in SENS Rejuvenation Research

In this recent interview with Aubrey de Grey touches on a number of areas of progress made by the research and development community in recent years, projects that lead towards rejuvenation therapies based on the Strategies for Engineered Negligible Senescence (SENS). In the SENS view, supported by a very sizable literature accumulated over the past century, aging is caused by underlying processes of damage accumulation. What we think of as aging is a diverse collection of downstream consequences of that damage. Periodically repairing the underlying damage, allowing the normal maintenance of the body to continue as it would in youth, remains the most promising approach to aging. Senolytic drugs to clear senescent cells are one example of a rejuvenation therapy based on SENS, and in animal models senolytics produce very impressive results on near all age-related conditions assessed to date. Ariel VA Feinerman: Can you name the most big breakthrough in each SENS programme since our interview in 2017? Aubrey de Grey: Well, let's see… RepleniSENS: probably the initiation of a clinical trial in Japan using iPSC-derived dopaminergic precursors to cure Parkinson's Disease. Other such trials are imminent in the USA. OncoSENS: definitely the main thing is 6-thiodeoxyguanine, or just THIO for short, which is essential "WILT 2.0". It turns telomerase into a suicide gene, killing cells quickly, rather than waiting for them to divide into telomere-less obli...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs